Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

April 25, 2023

How Target Trial Emulation Can Take the Guesswork Out of Comparative Effect Estimates in Medicare Drug Price Negotiation

An interview with Miguel Hernán, Harvard University Kolokotrones Professor of Biostatistics and Epidemiology On March...

Read article

April 18, 2023

Navigating Comparative Effectiveness in the Inflation Reduction Act: Methodological Approaches for Healthcare Challenges

The Inflation Reduction Act (IRA), passed in August 2022, marks a significant shift in the US healthcare landscape,...

Read article

September 15, 2022

U.S. Drug Pricing Reform: Potential Impact on Pharma HEOR Evidence Generation

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes U.S. drug...

Read article